PAUL SALADINO: Open Payments
NPI 1306951736 · NEWBURGH, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$497 in 15 payments from 7 companies in 2025. Trend: 2023 $457 · 2024 $330 · 2025 $497
Food & beverage: $497
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 7 | $317 |
| Alkermes, Inc. | 2 | $52 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| ABBVIE INC. | 1 | $29 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| Indivior Inc. | 1 | $15 |
| Novo Nordisk Inc | 1 | $15 |
Products named: Yeztugo, Descovy, ARISTADA, Auvelity, VRAYLAR, TRELEGY ELLIPTA, SUBLOCADE, Ozempic.
Industry payments across NY — which companies pay providers there.
